After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

In its Q1 fiscal 2026 financials, BD trimmed its EPS outlook by more than $2 at the high end due to the spin-off of its ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the commercial launch of the BD Vacutainer Urine ...

No, it’s not an April Fool’s joke—BD officially bid farewell to its longstanding diabetes business on Friday, as the newly formed Embecta made its public debut on the Nasdaq. The separation was nearly ...

Medical tech company BD (Becton, Dickinson and Co.) acquired MedKeeper, a provider of cloud-based pharmacy management applications, the Franklin Lakes firm announced July 28. The deal – terms of which ...

BD (Becton, Dickinson and Company) has agreed to combine its biosciences and diagnostic solutions business with Waters Corporation, creating a new life science and diagnostics company. The agreement ...

The medical technology company also reported it has repurchased $250 million in BD stock since the beginning of its fiscal 2026. Additionally, the board authorized the repurchase of up to 10 million ...

The investment will establish production of the company’s BD Neopak Glass Prefillable Syringe platform at the Nebraska site, with supply expected to begin in mid-2026. The company stated the expansion ...

FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has ...

The Parata Systems team will work with BD’s medication management solutions business, according to a July 18 news release. The company plans to focus on issues including clinician shortages, wage ...